Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 81,500 shares of the firm’s stock in a transaction dated Friday, November 9th. The shares were sold at an average price of $14.39, for a total value of $1,172,785.00. Following the transaction, the chief executive officer now directly owns 1,727,755 shares in the company, valued at $24,862,394.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Christopher Richard Anzalone also recently made the following trade(s):
- On Friday, August 31st, Christopher Richard Anzalone sold 100,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $14.45, for a total value of $1,445,000.00.
- On Tuesday, September 4th, Christopher Richard Anzalone sold 164,834 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $14.45, for a total value of $2,381,851.30.
Arrowhead Pharmaceuticals stock opened at $14.49 on Friday. The company has a quick ratio of 8.69, a current ratio of 8.69 and a debt-to-equity ratio of 0.02. Arrowhead Pharmaceuticals Inc has a 1-year low of $3.01 and a 1-year high of $22.39.
A number of research analysts have recently issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 17th. Chardan Capital set a $25.00 price objective on Arrowhead Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 14th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $24.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 11th. BidaskClub cut Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, October 6th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $25.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 4th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $21.45.
Several institutional investors have recently bought and sold shares of the company. RTW Investments LP boosted its holdings in shares of Arrowhead Pharmaceuticals by 184.6% during the second quarter. RTW Investments LP now owns 8,299,542 shares of the biotechnology company’s stock worth $112,874,000 after purchasing an additional 5,382,981 shares during the period. BlackRock Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 108.1% during the second quarter. BlackRock Inc. now owns 7,083,926 shares of the biotechnology company’s stock worth $96,342,000 after purchasing an additional 3,679,986 shares during the period. First Manhattan Co. boosted its holdings in shares of Arrowhead Pharmaceuticals by 11.6% during the third quarter. First Manhattan Co. now owns 5,053,925 shares of the biotechnology company’s stock worth $96,883,000 after purchasing an additional 523,675 shares during the period. FMR LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth about $37,922,000. Finally, Northern Trust Corp boosted its holdings in shares of Arrowhead Pharmaceuticals by 380.1% during the second quarter. Northern Trust Corp now owns 1,063,499 shares of the biotechnology company’s stock worth $14,464,000 after purchasing an additional 841,982 shares during the period. Institutional investors own 59.34% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Arrowhead Pharmaceuticals Inc (ARWR) CEO Christopher Richard Anzalone Sells 81,500 Shares” was originally posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://macondaily.com/2018/11/11/arrowhead-pharmaceuticals-inc-arwr-ceo-christopher-richard-anzalone-sells-81500-shares.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Featured Story: Ex-Dividend
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.